Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay).
BACKGROUND
Inherited differences in the metabolism and disposition of drugs, and genetic polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a number of clinically important drugs have been documented. The present study evaluated the activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western Indian population).


METHODS
All subjects received 20 mg of omeprazole, which was followed by blood collection at 3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was done by HPLC.


RESULTS
It was seen that 10.36% of this population were poor metabolizers(PM) whereas 89.63% were extensive metabolizers(EM).


CONCLUSIONS
A genotyping evaluation would better help in identifying population specific genotypes and thus help individualize drug therapy.
Panchabhai
Tanmay S
TS
Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India. tanmayp04@yahoo.com
Noronha
Shaun F
SF
Davis
Sanish
S
Shinde
Vishal M
VM
Kshirsagar
Nilima A
NA
Gogtay
Nithya J
NJ
D000328:Adult; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000378:metabolism*; D044466:Asian People / Q000235:genetics; D065731:Cytochrome P-450 CYP2C19; D004789:Enzyme Activation / Q000235:genetics; D005260:Female; D005838:Genotype; D006801:Humans; D007194:India / Q000208:ethnology; D008297:Male; D006899:Mixed Function Oxygenases / Q000235:genetics* / Q000378:metabolism*; D005810:Multigene Family; D011110:Polymorphism, Genetic / Q000235:genetics
D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19